Anal cancer: An examination of radiotherapy strategies

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 5, 2011, Pages 1290-1301

  Glynne Jones, Rob ^a   Lim, Faye ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANAL CANCER; CHEMORADIATION; CIS-PLATIN; INDIVIDUAL PATIENT DATA; INTENSITY-MODULATED RADIOTHERAPY; META ANALYSIS; PHASE II; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION THERAPY; RADIATION THERAPY ONCOLOGY GROUPS;

CHEMOTHERAPY; DISEASES; HOSPITAL DATA PROCESSING; PLATINUM COMPOUNDS;

RADIOTHERAPY;

CAPECITABINE; CETUXIMAB; CISPLATIN; FLUOROURACIL; MITOMYCIN C; OXALIPLATIN;

ANUS CANCER; ANUS CARCINOMA; BRACHYTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; COLOSTOMY; DOSE RESPONSE; DRUG DOSE COMPARISON; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION FIELD; RADIATION RESPONSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; CLINICAL TRIALS AS TOPIC; COLOSTOMY; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MITOMYCIN; NEOPLASM STAGING; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, INTENSITY-MODULATED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79952640466     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.10.017     Document Type: Review

References (78)

1. UKCCCR Anal Cancer Working Party. Epidermoid Anal Cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil and Mitomycin. Lancet 1996;348:1049-1054.
2. Bilimoria KY, Bentrem DJ, Rock CE, et al. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: Analysis of patients from the National Cancer Data Base. Dis Colon Rectum 2009;52:624-631.
3. Engstrom PF, Amoletti JP, Benson AB, et al. NCCN Practice Guidelines: Anal Cancer Version2.2009. www.nccn.org/professionals/physician
4. Glynne-Jones R, Northover J, Cervantes A. ESMO Guidelines Working Group. Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v87-v92.
5. Nigro ND, Seydel HG, Considine B Jr., et al. Combined radiotherapy and chemotherapy for squamous cell carcinoma of the anal canal. Cancer 1983;51:1826-1829. (Pubitemid 13093950)
6. Leichman L, Nigro N, Vaitkevicius VK, et al. Cancer of the anal canal: Model for preoperative adjuvant combined modality therapy. Am J Med 1985;78:211-215. (Pubitemid 15162919)
7. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a Phase III randomized trial of the European Organization for Research and Treatment of Cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol 1997;15:2040-2049. (Pubitemid 27209535)
8. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized Intergroup Study. J Clin Oncol 1996;14:2527-2539. (Pubitemid 26300120)
9. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin and radiotherapy vs fluorouracil, cisplatin and radiotherapy for carcinoma of the anal canal: A randomized controlled trial. JAMA 2008;199:1914-1921. (Pubitemid 351574921)
10. Peiffert D, Gerard JP, Ducreux M, et al. Induction chemotherapy (ICTA) and dose intensification of the radiation boost in locally advanced anal canal carcinoma (LAACC): Definitive analysis of the Intergroup Accord 03 trial (Fédération Nationale des centres de lutte contre le cancer) Fondation Française de Cancérologie Digestive. Radiother Oncol 2008;88(Suppl 2): S20 (abstract 65).
11. Conroy T, Ducreux M, Lemanski C, et al. Treatment intensification by induction chemotherapy (ICT) and radiation dose-escalation in locally advanced squamous cell anal canal carcinoma (LAAC): Definitive analysis of the intergroup ACCORD-03 trial. J Clin Oncol 2009;27:15S (Part I of II):176s (abstract 4033).
12. Ajani JA, Winter KA, Gunderson LL, et al. US Intergroup Anal Carcinoma Trial: Tumor diameter predicts for colostomy. J Clin Oncol 2009;27:1116-1121.
13. James R, Wan S, Glynne-Jones R, et al. A randomised trial of chemoradiation using Mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus. J Clin Oncol 2009;27:18S (part II of II); 797s (abstract LBA-4009).
14. James RD, Cunningham D, Davidson N, et al. Chemoradiation and Maintenance Chemotherapy for Patients with Anal Carcinoma: A Phase II Trial of the UK Co-ordinating Committee for Cancer Research (UKCCCR) Anal Cancer Working Party. J Clin Oncol 2000;19:268a (abstract 1045).
15. Glynne-Jones R, Meadows H, Wan S, et al. National Cancer Research Institute Anal Subgroup and Colorectal Clinical Oncology Group. EXTRA - a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous Mitomycin in anal cancer. Int J Radiat Oncol Biol Phys 2008;72:119-126.
16. Crehange G, Bosset M, Lorchel F, et al. Combining cisplatin and mitomycin with radiotherapy in anal carcinoma. Dis Colon Rectum 2006;50:43-49. (Pubitemid 46147020)
17. Eng C, Chang GJ, Das P, et al. Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal. J Clin Oncol 2009;27:15S (Part I of II); 196s (abstract 4116).
18. Sischy B, Doggett RLS, Krall JM, et al. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: Interim report on Radiation Therapy Oncology Group study no 8314. J Natl Cancer Inst 1989;81:850-856. (Pubitemid 19147389)
19. John M, Pajak I, Flam M, et al. Dose-escalation in chemoradiation for anal cancer: Preliminary results of RTOG 9208. Cancer J Sci Am 1996;2:205.
20. Konski A, Garcia M, John M, et al. Evaluation of planned treatment breaks during radiation therapy for anal cancer: Update of RTOG 92-08. Int J Radiat Oncol Biol Phys 2008;72:114-118.
21. Vaz F, Trindade C, Barata A, et al. Sequential and concomitant chemoradiation (CTR) therapy with fluorouracil (5FU) and cisplatin (CDDP) for anal squamous cell carcinoma (ASCC). J Clin Oncol 1998;17:304 (abstract 1173).
22. Peiffert D, Giovannini M, Ducreux M, et al. High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal carcinoma: Final results of a phase II study. Ann Oncol 2001;12:397-404. (Pubitemid 32288698)
23. Gerard JP, Romestaing P, Mornex F, et al. Radiochemotherapy in anal carcinoma (ACC). A randomised trial comparing fluorouracil-cisplatin (5FU-CDDP) and CDDP alone. Eur J Cancer 1999;S143 (abstract 523).
24. Meropol NJ, Niedzwiecki D, Shank B, et al. Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the Cancer and Leukemia Group B (CALGB 9281). J Clin Oncol 2008;26:3229-3234.
25. Bosset JF, Roelofsen F, Morgan DAL, et al. Shortened irradiation schedule, continuous infusion of 5-fluorouracil and fractionation of mitomycin in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups. Eur J Cancer 2003;39:45-51. (Pubitemid 36005424)
26. Martenson JA, Lipsitz SR, Leftkopoulou M, et al. Results of combined modality therapy for patients with anal cancer (E7283): An Eastern Cooperative Oncology Group study. Cancer 1995;76:1731-1736.
27. Martenson JA, Lipsitz SR, Wagner H, et al. Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292). Int J Radiat Oncol Biol Phys 1996;35:745-749. (Pubitemid 26251129)
28. Vuong T, Devic S, Belliveau P, et al. Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: Results of a phase II study. Int J Radiat Oncol Biol Phys 2003;56:823-831. (Pubitemid 36677378)
29. Matthews J. on behalf of TROG 99.02 participants. Early anal canal carcinoma - the Trans-Tasman Radiation Oncology Group (TROG) experience in TROG 99.02 study. Australas Radiol 2005;49:A3.
30. Doci R, Zucali R, La Monica G, et al. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: Results in 35 consecutive patients. J Clin Oncol 1996;14:3121-3125. (Pubitemid 26408805)
31. Olivatto LO, Meton F, Bezerra M, et al. Phase I study of cetuximab (CET) in combination with 5-flurouracil (5FU), cisplatin (CP) and radiotherapy (RT) in patients with locally advanced squamous cell anal carcinoma (LAAC). J Clin Oncol 2008;26:240s (abstract 4609).
32. Matzinger O, Roelofsen F, Mineur L, et al. For the EORTC Radiation Oncology and Gastrointestinal Tract Cancer Groups. Mitomycin with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). Eur J Cancer 2009;45:2782-2791.
33. Harmer MH, editor. TNM Classification of Malignant Tumours (ed 3). Geneva: Switzerland, UICC; 1978. p. 77-81.
34. Spiessl B, Hermanek P, Scheibe O, Wagner G, editors. UICC TNM-Atlas Illustrated Guide to the TNM/pTNM-Classification of Malignant Tumours. 2nd ed. Berlin Heidelberg: Springer-Verlag; 1985.
35. Beahrs OH, Henson D, Hutter RV, Myers RV, editors. Manual for the Staging of Cancer. JB Lippincott: Philadelphia; 1988.
36. Cummings BJ, Keane TJ, O'Sullivan B, et al. Epidermoid anal cancer: Treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin. Int J Radiat Oncol Biol Phys 1991;21:1115-1125.
37. Borzomati D, Valeri S, Ripetti V, et al. Persisting anal ulcer after radiotherapy for anal cancer: recurrence of disease or late radiation-related complication? Hepatogastroenterology 2005;52:780-784.
38. Tanum G, Tveit KM, Karlsen KO. Chemoradiotherapy of anal carcinoma: Tumour response and acute toxicity. Oncology 1993;50:14-17. (Pubitemid 23041105)
39. Trautmann TG, Zuger JH. Positron emission tomography for pre-treatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol 2005;7:309-313.
40. Schwarz JK, Siegel BA, Dehdashti F, et al. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys 2008;71:180-186. (Pubitemid 351492591)
41. Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010;102:1123-1128.
42. Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys 2007;68:794-800. (Pubitemid 46818735)
43. Nilsson PJ, Svensson C, Goldman S, et al. Epidermoid anal cancer: A review of a population-based series of 308 consecutive patients treated according to prospective protocols. Int J Radiat Oncol Biol Phys 2005;61:92-102. (Pubitemid 40039110)
44. John M, Flam M, Berkley B, et al. 5 year results and analyses of a phase III randomized RTOG/ECOG chemoradiation protocol for anal cancer. J Clin Oncol 1998;17:258a (abstract 989).
45. John M, Flam M, Palma N, et al. Ten year results on chemoradiation for anal cancer: Focus on late morbidity. Int J Radiat Oncol Biol Phys 1996;34:65-69. (Pubitemid 26019955)
46. Vuong T, Kopek N, Ducruet T, et al. Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:1394-1400. (Pubitemid 46467158)
47. Cummings BJ, Brierley JD. Anal canal. In: Perez CA, Brady LW, Halperin EC, Schmidt-Ullrich RK, editors. Principles and Practice of Radiation Oncology. 4th ed. Lippincott Williams & Wilkins: Philadelphia; 2004. p. 1630-1648.
48. Mai SK, Weitzel G, Hermann B, et al. Long-term outcome after combined radiochemotherapy for anal cancer - retrospective analysis of efficacy, prognostic factors and toxicity. Onkologie 2008;31:251-257. (Pubitemid 351744825)
49. Tournier-Rangeard L, Mercier M, Peiffert D, et al. Radiochemotherapy of locally advanced anal canal carcinoma: Prospective assessment of early impact on the quality of life (randomised trial ACCOR 03). Radiother Oncol 2008;87:391-397.
50. Slevin ML, Plowman PN, Ryan CM, et al. Chemoradiotherapy for anal cancer improves quality of life compared to radiotherapy alone. J Clin Oncol 1998;17 (abstract 266).
51. Allal AS, Sprangers MAG, Laurencet F, et al. Assessment of long-term quality of life in patients with anal carcinoma treated by radiotherapy with or without chemotherapy. Br J Cancer 1999;80:1588-1594. (Pubitemid 29308641)
52. Sprangers MA, te Velde A, Aaronson NK. The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Eur J Cancer 1999;35:238-247. (Pubitemid 29136774)
53. Vordermark D, Sailer M, Flentje M, et al. Curative intent radiation therapy in anal carcinomas: Quality of life and sphincter function. Radiother Oncol 1999;52:239-243. (Pubitemid 29486643)
54. Broens P, van Limbergen E, Penninckx F, et al. Clinical and manometric effects of combined external beam irradiation and brachytherapy for anal cancer. Int J Colorectal Dis 1998;13:68-72. (Pubitemid 28239677)
55. Das P, Cantor SB, Parker CL, et al. Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer 2010;116:822-829.
56. Provencher S, Oehler C, Lavertu S, et al. Quality of life and tumor control after split course chemoradiation for anal cancer. Radiat Oncol 2010;5:41.
57. Vordermark D, Sailer M, Flentje M, et al. Impaired sphincter function and good quality of life in anal carcinoma patients after radiotherapy: A paradox? Front Radiat Ther Oncol 2002;37:132-139.
58. Jephcott CR, Paltiel C, Hay J. Quality of life after non-surgical treatment of anal carcinoma: a case control study of long-term survivors. Clin Oncol (R Coll Radiol) 2004;16:530-535. (Pubitemid 39517661)
59. Graf R, Wust P, Hilderbrant B, et al. Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. Oncology 2003;65:14-22. (Pubitemid 36829086)
60. Janssen S, Meier Zu Eissen J, Kolbert G, et al. Anal cancer treated with radio-chemotherapy: Correlation between length of treatment interruption and outcome. Int J Colorectal Dis 2009 Aug 1 [Epub ahead of print].
61. Ben-Josef E, Moughan J, Ajani J, et al. The impact of overall treatment time on survival and local control in anal cancer patients: a pooled data analysis of RTOG trials 8704 and 9811. Int J Radiation Oncol Biol Phys 2009;75(3 suppl) Proc ASTRO S5(abstract 55).
62. Papillon J, Montbarbon JF. Epidermoid carcinoma of the anal canal: A series of 276 cases. Dis Colon Rectum 1987;30:324-333. (Pubitemid 17078513)
63. Kachnic L, Winter K, Myerson R, et al. RTOG 0529: A phase II evaluation of dose painted IMRT in combination with 5-fluorouracil and Mitomycin C for reduction of acute morbidity in carcinoma of the anal canal. Int J Radiation Oncol Biol Phys 2009;75(3) suppl Proc ASTRO S5(abstract 10).
64. Wong CS, Tsang RW, Cummings BJ, et al. Proliferation parameters in epidermoid carcinomas of the anal canal. Radiother Oncol 2000;56:349-353.
65. Ajani JA, Winter KA, Gunderson LL, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: The intergroup trial (RTOG 98-11). Cancer 2010 Jun 8 [Epub ahead of print].
66. Peiffert D, Bey P, Pernot M, et al. Conservative treatment by irradiation of epidermoid cancers of the anal canal: Prognostic factors of tumoral control and complications. Int J Radiat Oncol Biol Phys 1997;37:313-324. (Pubitemid 27138714)
67. Hwang JM, Rao AR, Cosmatos HA, et al. Treatment of T3 and T4 anal carcinoma with combined chemoradiation and interstitial implantation: A 10 year experience. Brachytherapy 2004;3:95-100. (Pubitemid 39221353)
68. Saarilahti K, Arponen P, Vaalavirta L, et al. The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol 2008;87:383-390.
69. Chen YJ, Liu A, Tsai PT, et al. Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: Dosimetric evaluation of coverage of pelvis and inguinal/ femoral nodes. Int J Radiat Oncol Biol Phys 2005;63:274-281. (Pubitemid 41583568)
70. Milano MT, Jani AB, Farrey KJ, et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: Toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2005;63:354-361. (Pubitemid 41317151)
71. Mell LK, Schomas DA, Salama JK, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008;71:1431-1437. (Pubitemid 351417769)
72. Menkarios C, Azria D, Laliberte B, et al. Optimal organsparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: A comparison of conventional and IMRT plans. Radiat Oncol 2007;2:41.
73. Hodges JC, Das P, Eng C, et al. Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement. Int J Radiat Oncol Biol Phys 2009;75:791-794.
74. Kachnic LA, Winter KA, Myerson RJ, et al. RTOG 0529: A phase II study of dose-painted IMRT (DP-IMRT), 5-fluorouracil, and mitomycin-C for the reduction of acute morbidity in anal cancer. ASCO 2010. Gastrointestinal Cancers Symposium; abstract 405.
75. Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: A multicenter experience. J Clin Oncol 2007;25:4581-4586. (Pubitemid 350035316)
76. Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: A radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009;74:824-830.
77. Lukan N, Ströbel P, Willer A, et al. Cetuximab-based treatment of metastatic anal cancer: Correlation of response with KRAS mutational status. Oncology 2009;77:293-299.
78. Van Damme N, Deron P, Van Roy N, et al. Epidermal growth factor receptor and K-ras status in two cohorts of squamous cell carcinomas. BMC Cancer 2010;10:189.